【NOVAMSC 0026 交流专区】荣腾科技

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2024

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2024	31 Dec 2023	31 Dec 2024	31 Dec 2023
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	10,667	10,185	30,323	26,746
2	Profit/(loss) before tax	584	277	-4,350	-3,830
3	Profit/(loss) for the period	584	277	-4,350	-3,830
4	Profit/(loss) attributable to ordinary equity holders of the parent	189	22	-3,764	-3,982
5	Basic earnings/(loss) per share (Subunit)	0.01	0.00	-0.29	-0.33
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.0255		0.0261

icy97

NOVA MSC BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Conversion of Preference Shares
Details of corporate proposal	Conversion of Irredeemable Convertible Preference Shares
No. of shares issued under this corporate proposal	55,482,900
Issue price per share	Malaysian Ringgit (MYR)   0.0400
Par Value (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	1,617,868,648
Issued Share Capital	Malaysian Ringgit (MYR) 129,812,948.270
Listing Date	04 Mar 2025

icy97

NOVA MSC BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Conversion of Preference Shares
Details of corporate proposal	Conversion of Irredeemable Convertible Preference Shares
No. of shares issued under this corporate proposal	494,510,492
Issue price per share	Malaysian Ringgit (MYR)   0.0400
Par Value (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	2,145,560,206
Issued Share Capital	Malaysian Ringgit (MYR) 145,643,677.010
Listing Date	26 Mar 2025

icy97

NOVA MSC BERHAD

Particulars of substantial Securities Holder

Name	MR LOH GUAN HUAT SUNNY
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	24 Mar 2025	436,878,787	Others	Direct Interest
	Name of registered holder	Citigroup Nominees (Asing) Sdn Bhd Exempt an for OCBC Securities Private Limited
	Description of "Others" Type of Transaction	Conversion of ICPS

Circumstances by reason of which change has occurred	Conversion of ICPS into Ordinary Shares
Nature of interest	Direct Interest
Direct (units)	515,666,665
Direct (%)	24.034
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	515,666,665
Date of notice	25 Mar 2025
Date notice received by Listed Issuer	25 Mar 2025

icy97

Change in Financial Year End

NOVA MSC BERHAD

Old financial year end	31 Mar 2025
New financial year end	30 Jun 2025

Remarks :

The Board of Directors of the Company has approved the change of the Company's financial year end from 31 March to 30 June. Accordingly, the next set of audited financial statements will be made up from 01 April 2024 to 30 June 2025 covering a period of 15 months. Thereafter, the financial year end of the Company shall end on 30 June for each subsequent year. Such change is to facilitate better management of resources for smooth flow of financial reporting and business operations.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2025

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		Three Months	Three Months	Three Months	Three Months
		01 Jan 2025 To	01 Jan 2024 To	01 Jan 2025 To	01 Jan 2024 To
		31 Mar 2025	31 Mar 2024	31 Mar 2025	31 Mar 2024
		MYR'000	MYR'000	MYR'000	MYR'000

1	Revenue	7,111	6,299	37,434	33,045
2	Profit/(loss) before tax	-2,212	-2,993	-6,562	-6,823
3	Profit/(loss) for the period	-2,212	-3,004	-6,562	-6,834
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,240	-2,316	-5,004	-6,298
5	Basic earnings/(loss) per share (Subunit)	-0.08	-0.19	-0.30	-0.53
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent	0.0262		0.0261

icy97

NOVA MSC BERHAD

Date of change	01 Jun 2025
Name	MR LAI TEIK KIN
Age	61
Gender	Male
Nationality	Singapore
Type of change	Redesignation
Previous Position	Group Chief Executive Officer
New Position	Executive Director
Directorate	Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	Surveying	University of Queensland, Australia

Working experience and occupation	Earlier in his career and before co-founding the Nova MSC Group, Mr Lai Teik Kin was in involved in implementation of large scale & regional e-government projects. Since 1999, Teik Kin has served as both Executive Director and Chief Executive Officer of novaHEALTH Pte Ltd, a wholly owned subsidiary of the Nova MSC Bhd, spearheading the Groups foray into healthcare industry. From 2005-2012, Teik Kin also served as an Independent Non-Executive Director on the Board of MTouche Berhad, a public-listed company in Malaysia which is a forerunner and leader in wireless network technologies, mobile messaging services and interactive media applications.In 2016, Teik Kin was appointed Business Mentor to the Singapore National Eye Centre (SNEC) Ophthalmic Technologies Incubator to provide business insights and guidance. In 2018, Teik Kin spearheaded a spin-off of EyRIS jointly with Singapore Eye Research Institute (SERI) and National University of Singapore-School of Computing (NUS-SoC) to develop and commercialize the artificial intelligence (AI) solutions for the healthcare industry. SELENA+, our first AI solution, performs automated image analysis for eye diseases such diabetes retinopathy with add-on modules for glaucoma and age-related macular degeneration.
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Nova MSC BerhadDirect interest: 64,999,883 ordinary sharesIndirect interest:  Nil EyRIS Pte Ltd (42%-owned indirect subsidiary)Direct interest: 19,999 ordinary sharesDirect interest:  Nil